Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics
June 28, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s...
Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options
June 16, 2022 01:03 ET | F. Hoffmann-La Roche Ltd
Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV). 1Nearly...
Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease
June 16, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease For more than a decade Roche has been working in...
Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and quantitatively measure viral load levels of COVID-19
June 15, 2022 11:45 ET | F. Hoffmann-La Roche Ltd
The cobas SARS-CoV-2 Duo test combines the standard qualitative result of a traditional SARS-CoV-2 PCR test with a quantitative result, which measures the viral load of a patient suspected of...
Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
June 10, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with...
U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
June 09, 2022 01:03 ET | F. Hoffmann-La Roche Ltd
FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom treatment with Rozlytrek may be...
European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
June 09, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive...
European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma
June 08, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Lunsumio® (mosunetuzumab) is the first CD20xCD3 T-cell engaging bispecific antibody available to treat the most common slow-growing form of non-Hodgkin lymphoma, follicular lymphoma (FL)Lunsumio...
FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
May 31, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk Prescribing information updated with FIREFISH...
New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
May 27, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma...